Scotland · NHS Scotland MSAN
Lithium carbonate (Priadel®) 200mg and 400mg modified release tablets
MSAN(2020)100 · Level 3 · issued 15 Oct 2020
What the notice states
The supply position for each affected product, as recorded in the notice — read the full signed PDF above for the clinical advice and actions.
| Product | Position | Resupply |
|---|---|---|
| decision to reverse the discontinuation of Priadel® 200mg and 400mg tablets from the UK | Discontinued | — |
| market with immediate effect, whilst facilitating pricing discussions. As such the discontinuation | Discontinued | — |
| meet current UK demand and is working to ensure further stocks are available to maintain | Available | — |
| 5. Although DHSC cannot confirm a discontinuation will not take place in future, it is important to | Discontinued | — |
| months’ notice of an intention to discontinue a product from the UK market. | Discontinued | — |
| 6. Whilst Priadel® 200mg and 400mg tablets do remain available, Essential Pharma are aware | Available | — |
| ensure supplies remain available for the UK. | Available | — |
From the NHS Scotland notice PDF (linked above); dates and “valid until” text are as stated, fuzzy wording kept as written. Scotland is covered separately from England — see methodology. Not an official NHS service, and not clinical advice — follow the guidance issued to your pharmacy.